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Abstract
A prerequisite for protein synthesis is the transcription of ribosomal rRNA genes by RNA polymerase I (Pol I), which
controls ribosome biogenesis. UBF (upstream binding factor) is one of the main Pol I transcription factors located in
the nucleolus that activates rRNA gene transcription. E2F7 is an atypical E2F family member that acts as a
transcriptional repressor of E2F target genes, and thereby contributes to cell cycle arrest. Here, we describe an
unexpected role for E2F7 in regulating rRNA gene transcription. We have found that E2F7 localises to the perinucleolar
region, and further that E2F7 is able to exert repressive effects on Pol I transcription. At the mechanistic level, this is
achieved in part by E2F7 hindering UBF recruitment to the rRNA gene promoter region, and thereby reducing rRNA
gene transcription, which in turn compromises global protein synthesis. Our results expand the target gene repertoire
inﬂuenced by E2F7 to include Pol I-regulated genes, and more generally suggest a mechanism mediated by effects on
Pol I transcription where E2F7 links cell cycle arrest with protein synthesis.
Introduction
The rate of protein synthesis is directly proportional to
cell growth and proliferation. This is, in turn, intimately
linked to ribosome biogenesis, which is controlled at the
transcription level by Pol I1. The Pol I transcription
machinery integrates information from cellular signalling
cascades to regulate ribosome production and this guides
cell growth and proliferation1. Ribosome biogenesis
occurs in the nucleolus, and transcription of rRNA genes
by Pol I is a major point of control. Pol I accounts for up
to 60% of transcriptional activity in the cell, and rRNA
contributes for up to 80% of the total RNA2. Interestingly,
ribosome biosynthesis consumes about 80% of a cell’s
energy and nearly all metabolic and signalling pathways
lead to or from the nucleolus3.
The eukaryotic ribosome has a core complex of about
80 proteins and four rRNAs. The mature 80S ribosome is
comprised of a large (60S) and a small (40S) subunit; the
large subunit contains the 28S, 5.8S and 5S rRNAs, while
the small subunit contains the 18S rRNA4. In humans, the
28S, 5.8S and 5S rRNA molecules are encoded within
tandemly repeated 47 kb nucleolar-organising regions
(NORs), which reside on the ﬁve acrocentric chromo-
somes, while the 5S rRNA is encoded by a tandemly
repeated cluster on chromosome 15,6. NORs are essential
for nucleolar structure where they localise to form the
nucleolus7.
During proliferation, cellular stress and differentiation,
cells downregulate the synthesis of rRNA and ribosome
biogenesis, thus designating the nucleolus as a central hub
that coordinates cellular growth1,8. Ribosome biogenesis
is tightly regulated by key proteins involved in cell growth
and proliferation. For example, tumour suppressor pro-
teins, such as p53, inﬂuence ribosome biogenesis in a
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negative fashion through interfering with the Pol I tran-
scription factors, UBF and SL-19. Conversely, oncopro-
teins, such as MYC, locate to the rRNA promoter to
enhance Pol I activity10. In this way, ribosome biogenesis
is intimately connected with cell growth and proliferation,
and is affected by oncogenic events that occur in tumour
suppressor and growth-promoting pathways. Importantly,
the nucleolus and Pol I activity are increasingly viewed as
attractive therapeutic targets, as proliferative cells are
dependent on ribosome biogenesis for growth11,12.
E2F is a generic term for a family of master regulators
that co-ordinate transcription with cell cycle progres-
sion13. E2F is a key target for the retinoblastoma tumour
suppressor pRb, and deregulation of the pathway is of
primary importance in proliferative disease like cancer,
where aberrant pRb activity occurs through a variety of
oncogenic mechanisms13. The E2F family has eight dis-
tinct members, with E2F7 regarded as atypical because it
is endowed with pRb-independent repressive activity,
which it exerts on E2F target genes leading to cell cycle
arrest14–17. In addition, during the DNA damage
response, E2F7 activity is upregulated where it impacts on
cell cycle progression and DNA repair18,19.
Here, we describe an unexpected and surprising role for
E2F7 in regulating ribosomal gene transcription. Thus, we
have found that E2F7 localises to the nucleolar cap region,
a major site of rRNA synthesis, which is dependent on its
DNA-binding activity. E2F7 located to the Pol I promoter,
and silencing E2F7 led to enhanced recruitment of UBF
and thereafter increased Pol I activity. Accordingly, E2F7
affects global cellular protein synthesis in a negative
fashion. Our results provide the ﬁrst evidence that links
E2F7 activity with ribosomal biogenesis, and thereby
provide a mechanism for integrating cell cycle progression
with cell growth and protein synthesis.
Results
E2F7 localises to the nucleolus
In examining the intracellular location of E2F7, we
observed that in addition to its expected nuclear locali-
sation, E2F7 was present at nucleolar cap structures which
we observed with both Flag and HA-tagged E2F7, as well
as GFP-tagged E2F7 compared to GFP alone (Fig. 1a and
SI Fig. 1A). Importantly, we examined the localisation of
endogenous E2F7 using two different E2F7 antibodies.
Similar to what was observed upon the expression of
ectopic E2F7, endogenous E2F7 was present throughout
the nucleus (Fig. 1b). Importantly, E2F7 could also be seen
to localise to the perinucleolar region (Fig. 1b). It is
known that cellular stress, such as DNA damage, and
direct inhibition of Pol I, result in nucleolar segregation
and the increased formation of nucleolar caps around the
nucleolar remnant8. We therefore used low-dose actino-
mycin D treatment to inhibit Pol I activity20. Under these
conditions, we observed enhanced localisation of E2F7 to
nucleolar caps (Fig. 1c and SI Fig. 1A, B) and endogenous
E2F7 colocalised in the perinucleolar region with the
nucleolar protein nucleolin (Fig. 1d).
E2F7 contains a bi-partite DNA-binding domain, and its
integrity is required for transcriptional repression15,16. Of
note, we found that DNA-binding domain (DBD) point
mutants, unable to act as transcriptional repressors (SI
Fig. 1C), were not able to localise at the nucleolus, even in
the presence of actinomycin D (Fig. 1c, e). The ability of
E2F7 to act at the level of DNA binding is thus necessary
for its nucleolar localisation.
E2F7 inhibits Pol I activity
Since the nucleolar location of E2F7 is dependent
upon its DNA-binding domain, we reasoned that E2F7
could impact on rRNA gene transcription. We therefore
examined the effect on Pol I activity by silencing
endogenous E2F7 and measuring 47S pre-rRNA tran-
script levels. The level of pre-rRNA was signiﬁcantly
increased after E2F7 depletion (nearly twofold, Fig. 2a).
This was speciﬁc to ongoing Pol I activity as the pre-
sence of actinomycin D inhibited rRNA gene tran-
scription (SI Fig. 2A). This suggested that E2F7 has a
negative impact on Pol I activity. In support of this idea,
we used 5-ﬂuorouridine (FUrd) incorporation in situ to
measure nascent RNA synthesis20, where we observed
that in cells expressing ectopic E2F7 there was a marked
loss of FUrd incorporation (Fig. 2b). In contrast,
expression of a DBD mutant derivative E2F7 had little
effect on nucleolar FUrd incorporation (Fig. 2b), con-
ﬁrming that the ability of E2F7 to inhibit Pol I activity
and prevent rRNA synthesis required an intact DNA-
binding domain.
Next, we explored the possibility that E2F7 is present in
the chromatin environment of the Pol I promoter. By
chromatin immunoprecipitation (ChIP) we detected
E2F7 at the Pol I promoter (Fig. 3a, b). The levels were
similar to that of E2F7 at the E2F1 promoter under
normal growth conditions, and markedly higher when
compared to the E2F target gene CDC6 (Fig. 3a). Inter-
estingly, the presence of E2F7 at the E2F1 promoter was
signiﬁcantly decreased when Pol I activity was prevented
with actinomycin D, while its presence at the rRNA gene
promoter remained unaffected (Fig. 3a, b). Since tran-
scription factor UBF is essential for transcription by RNA
Pol I21,22, we examined any effect of E2F7 on UBF
recruitment to the Pol I promoter, and observed a sig-
niﬁcant enhancement in the recruitment of UBF to the
rRNA gene promoter region after E2F7 depletion
(Fig. 3c). Together, these results suggest that E2F7 acts
negatively on Pol I rRNA gene transcription and that the
integrity of its DNA-binding domain is required for this
to occur.
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E2F7 inhibits total protein synthesis
RNA Pol I activity results in enhanced ribosome pro-
duction leading to increased protein synthesis23. To
explore what effect E2F7 has on total protein synthesis we
performed puromycin incorporation assays to determine
both steady-state and nascent protein production24. We
found that E2F7 depletion resulted in a signiﬁcant
increase in the level of protein synthesis (Fig. 4a–c and SI
Fig. 2B). To conﬁrm the speciﬁcity of this effect we
depleted E2F7 with two different siRNAs, both of which
resulted in E2F7 depletion and enhanced protein synthesis
(Fig. 4d and SI Fig. 2C). The ability of E2F7 to inﬂuence
protein synthesis appeared not to be cell-type-speciﬁc as
similar results were observed in both U2OS (osteo-
sarcoma) and MCF7 (breast cancer) human cancer cell
lines (Fig. 4a–d and SI Fig. 2B, C). Together, these results
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Fig. 1 E2F7 localises to the nucleolus. a U2OS cells expressing HA, Flag or GFP-tagged E2F7. HA-E2F7 and Flag-E2F7 were detected with HA and
Flag antibodies, respectively. DAPI staining was used to visualise nuclei. b Endogenous E2F7 was detected in asynchronously growing U2OS cells
using rabbit anti-E2F7 antibody H300 (Santa Cruz) and rabbit anti-E2F7 antibody PT (Proteintech). c U2OS cells expressing HA wild-type E2F7 (HA-
WT7), GFP-E2F7 or DNA-binding domain mutant R185A were treated with 1 nM actinomycin D overnight. HA-E2F7 was detected with anti-HA
antibody. d Endogenous E2F7 (rabbit anti-E2F7 PT) and nucleolin were detected in U2OS cells treated with 1 nM actinomycin D. e U2OS cells were
transfected HA-E2F7 constructs containing wild-type E2F7 (HA-WT7) or the DNA-binding domain mutants R185A, R334A and the double-mutant
R185A/R334A. Cells were treated with 1 nM actinomycin D overnight before ﬁxation and processing for immunoﬂuorescence. Ectopic E2F7 was
detected with anti-HA antibody. Scale bars= 10 μm. Arrows indicate E2F7 perinucleolar localisation
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suggest a mechanism whereby E2F7 through its ability to
downregulate Pol I transcription is able to affect global
protein synthesis.
E2F7 inﬂuences cell cycle progression and is itself
regulated in a cell cycle-dependent fashion15–17,25. Despite
this, in asynchronously growing cells under conditions
where no cell cycle perturbation upon E2F7 depletion was
apparent (Fig. 5a), increased protein synthesis was
observed (Fig. 4a–d), suggesting that the effect on protein
synthesis was not inﬂuenced by signiﬁcant alterations in
cell cycle progression. Moreover, since cell starvation is a
key regulator of protein synthesis26, we also examined if
during short-term starvation E2F7 had any effect on
protein synthesis. During a 4 h starvation (EBSS) with or
without a 1 h re-feed, depleting E2F7 had no obvious
effects on the cell cycle proﬁle (Fig. 5a). Yet, under these
conditions, E2F7 depletion resulted in a marked increase
in protein synthesis (Fig. 5b), demonstrating the effect of
E2F7 on Pol I activity, and thus protein synthesis, could be
uncoupled from cell cycle progression.
E2F7 causes nucleolar segregation
We noted that under normal growth conditions many
E2F7-expressing cells displayed decreased nucleolar UBF
levels and altered localisation (Fig. 6a; compare E2F7
transfected vs non-transfected cell, marked with arrows
bottom panel). This suggested that E2F7 causes nucleolar
segregation as a result of its ability to inhibit rRNA gene
transcription8. To explore this idea further, we examined
nucleophosmin (NPM) localisation in the presence of
E2F7, as NPM has been shown to relocalise from the
nucleolus to the nucleoplasm during stress27. Indeed,
ectopic E2F7 resulted in nucleolar segregation as visualised
by dispersal and relocalisation of NPM (Fig. 6b). Notably,
E2F7 also resulted in the relocalisation of the nucleolar
protein nucleolin in the absence of stress (Fig. 6c). This
occurred to a similar extent to that observed when Pol I
was inhibited with actinomycin D (SI Fig. 3A) and was
dependent on an intact DNA-binding domain (Fig. 6c).
Similar results were also seen with GFP-tagged E2F7, but
not GFP alone (SI Fig. 3B). Thus, E2F7 can impair
nucleolar structure and inhibit rRNA transcription.
Discussion
Cancer cells are by nature rapidly dividing and as such
require elevated protein production mediated by
enhanced rRNA gene transcription and Pol I activity28.
The regulation of Pol I activity is a key determinant of
ribosome biogenesis as it provides rRNA for the mature
ribosome1,2. Moreover, rRNA gene transcription is com-
monly deregulated in cancer through oncogenic events28.
As Pol I activity is high in cancer and it has been shown
that maintaining elevated Pol I activity is critical for
cancer cell survival, it is an attractive therapeutic target29.
Thus, uncovering new pathways responsible for regulating
Pol I activity could provide novel therapeutic options to
treat human cancer. In this study we demonstrate that the
atypical E2F family member, E2F7, is able to repress Pol I
transcriptional activity and impair nucleolar structure
resulting in a decrease in rRNA transcription and global
protein production.
We have found, surprisingly, that E2F7 is able to inhibit
Pol I activity through modulating UBF recruitment to the
Pol I promoter (Fig. 6d). UBF is necessary for Pol I acti-
vation and key for upregulation of rRNA gene transcrip-
tion21,22. E2F activity has been implicated in the
regulation of Pol I, where E2F1 binds to the rRNA gene
promoter to modulate its activity30. More recently, the
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Fig. 2 E2F7 inhibits Pol I activity. a i U2OS cells were treated with
control (GFP) or E2F7 siRNA for 72 h before RNA isolation and RT-
qPCR. 47S transcript levels were quantiﬁed using two different primer
sets (A and B) and results are expressed as fold over control after
normalising for GAPDH levels. Graph represents mean ± s.e.m., n= 3
independent experiments, *p < 0.05, Student’s t test. ii Blots represent
the level of E2F7 and tubulin. b Nascent nucleolar RNA synthesis was
detected after growing asynchronous U2OS cells transfected with HA
wild-type E2F7 (WT) or the DNA-binding mutant R185A (DBD) in the
presence of 2 mM 5-FUrd for 30 min before ﬁxation and processing for
immunoﬂuorescence. RNA incorporated 5-FUrd was detected using
anti-BrdU antibody BU-33 and E2F7 with anti-HA. Arrows highlight
regions where there is a lack of FUrd incorporation (WT) or regions
where FUrd incorporation is unaffected (DBD)
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E2F target gene CDC6 product was shown to regulate
rRNA gene transcription initiation, suggesting a
mechanism by which DNA replication and transcription
are coordinated31. The fact that E2F7, a negative regulator
of E2F1 activity and an important regulator of DNA
replication14–17, results in the negative regulation of Pol I
support this. Moreover, in certain tumour cell lines,
particularly those derived from haematopoietic and lym-
phoid malignancies, E2F7 is expressed at very low levels
(www.cbioportal.org/index.do). Interestingly, in clinical
disease, such as glioblastoma, E2F7 is similarly expressed
at lower levels relative to normal tissue (https://www.
oncomine.com). The reduced level of E2F7 may therefore
contribute to enhanced ribosome biogenesis and protein
synthesis characteristic of malignant disease.
During the cell cycle, the nucleolus undergoes extensive
changes at the onset of mitosis and rDNA transcription is
inhibited between prometaphase and telophase32. While
our data suggest that the effects of E2F7 on Pol I activity
and thus protein synthesis can be uncoupled from cell cycle
regulation, the ability of E2F7 to co-ordinate E2F activity
with growth signals may be an additional important
mechanism, which allows E2F7 to exert additional effects
on cell growth. For example, during DNA damage E2F7 is
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Fig. 3 E2F7 localises to rRNA promoter. a U2OS cells were transfected with Flag-E2F7 or vector control. ChIP was performed cells with (+) and
without (−) actinomycin D (ActD) treatment (20 nM, 4 h). PCR was performed using primers that amplify rDNA promoter −144 to +20. b An
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upregulated where it is involved in DNA repair18,19, which
could provide a means for coordinating cell cycle arrest,
promoting DNA r1epair and preventing protein synthesis.
Together, our study suggests that enhanced levels of
E2F7 lead to inhibition of Pol I activity and nucleolar
segregation. This provides an important mechanism
during the cellular response to stress to co-ordinate
protein synthesis and cell cycle arrest. Deregulated E2F7
activity in cancer would thus be expected to impact on
tumour cell growth both through its ability to modulate
E2F1 activity as well as by inﬂuencing protein production
through altered Pol I activity.
Materials and Methods
Plasmids, antibodies and reagents
The following plasmids have been previously described:
pcDNA-HA-E2F7, pcDNA-HA-E2F7 R185A, R334A,
R185A/R334A, CMV-E2F1 and E2F1-luciferase16,18,19.
Mouse anti-HA antibody HA11 was from BAbCO. Anti-
puromycin antibody was from Merck Millipore. Goat
anti-E2F7, rabbit anti-E2F7 H300, rabbit anti-UBF, mouse
anti-nucleophosmin and mouse anti-nucleolin antibodies
were from Santa Cruz. Rabbit anti-E2F7 antibody was
from Proteintech. Mouse anti-actin, anti-BrdU BU-33 and
anti-Flag antibodies were from Sigma. HRP-conjugated
secondary antibody was from DAKO. Alexa Fluor-
conjugated secondary antibodies were from Molecular
Probes. Actinomycin D was from Sigma. EBSS growth
medium was from ThermoFisher Scientiﬁc.
Cell lines and transfections
U2OS and MCF7 cells were grown in 5% FCS-DMEM
plus antibiotics under 5% CO2 unless otherwise denoted.
Plasmid transfections were performed using GeneJuice
(Merck Biosciences). siRNA transfections were performed
using Oligofectamine (Invitrogen) using 25 nM siRNA.
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Human E2F7 siRNA has been previously described18 and
siRNA targeting GFP was used as a non-targeting control.
Immunostaining
Cells were seeded onto 13 mm glass coverslips and ﬁxed
with 3.7% formaldehyde. Permeabilisation was performed
for 5 min with 0.5% Triton X-100 in PBS followed by
incubation with primary antibody for an hour at room
temperature (or overnight). Coverslips were washed with
0.025% Tween in PBS extensively before adding secondary
antibody. Coverslips were mounted on microscope slides
using Vectashield with or without DAPI (4,6-diamino-2-
phenylindole). Images were obtained using an Olympus
BX51 inverted ﬂuorescence microscope using a ×63 oil-
immersion lense. To visualise nascent RNA, U2OS cells
grown on coverslips were labelled with 2 mM ﬂuorour-
idine (FUrd) for 30min before ﬁxing with 1% for-
maldehyde and staining with BrdU antibody BU-33
(Sigma).
FACS analysis
Cells were seeded into 6 cm dishes and treated as
appropriate before harvesting. Growth media were col-
lected and adherent cells were lifted by adding 1mL of
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Fig. 5 E2F7 effects on protein synthesis can be dissociated from cell cycle. a U2OS cells treated with either control (GFP) or E2F7 siRNA for 72 h.
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trypsin per dish. The cells were pelleted (800 × g) for 5
min at 4 °C and washed once with PBS. The cells were
ﬁxed in ice-cold 70% ethanol/PBS (v/v). Fixed cells were
washed with PBS and stained in 2% (v/v) propidium
iodide in the presence of 125 U/mL DNAse-free RNAse
A. Stained cells were analysed using ﬂow cytometry
(Accuri C6, BD Bioscience).
Puromycin incorporation assays
Cells were treated with either vehicle or cyclohexamide
(100 μg/mL) for 10min before washing out and replacing
with fresh medium containing 10 μg/mL puromycin.
Puromycin incorporation was carried out for 2–5min at
37 °C before harvesting.
Chromatin immunoprecipitation
Cells were ﬁxed with 1% formaldehyde for 10min,
quenched with 0.125M glycine followed by permeabili-
sation in SDS lysis buffer (1% SDS, 10 mM EDTA,
50mM Tris, pH 8.0.). Samples were sonicated using
Diagenode Bioruptor for 10–20 cycles of 30 s on
30 s off. Immunoprecipitated complexes were collected
using 25 μL protein A/G slurry. Samples were washed
extensively with low salt buffer (0.1% SDS, 1% Triton, 2
mM EDTA, 20mM Tris, pH 8, 150mM NaCl) and LiCl
wash buffer (10 mM Tris pH 8.0, 1% Na-deoxycholate, 1%
NP-40, 250mM LiCl, 1 mM EDTA). Complexes
were washed a further two times with TE before reverse
cross-linking and RNAse digestion at 65 °C for 3 h fol-
lowed by overnight at 55 °C. DNA was isoloated using
Qiagen columns according to the manufacturer’s
instructions. ChIP samples along with inputs were ana-
lysed using either standard RT-PCR protocols or taken on
to qPCR using SYBR green II. The following primer sets
were used: hrDNA: A forward: CCGTGGGTTGT
CTTCTGACT reverse: AAGCGAAACCGTGAGTCG B
forward CAGCGCGCCGTAGCTC reverse. GCCTCA-
GACGGCCAGGAT C forward: GATCCTTTCTGGC-
GAGTCC reverse: GGAGCCGGAAGCATTTTC. D
forward: GTGTGTGGCTGCGATGGT reverse: CCAAC
CTCTCCGACGACAG. E forward: CGACCTGTCGTC
GGAGAG reverse: GGACGCGCGAGAGAACAG.
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nucleus cytoplasm
protein
synthesis
nucleolus
D
Fig. 6 E2F7 results in nucleolar segregation. a U2OS cells expressing HA wild-type E2F7 (E2F7). E2F7 was detected using anti-HA antibody and
endogenous UBF was detected with anti-UBF antibody. b U2OS cells expressing HA wild-type E2F7 (E2F7). Nucleophosmin was detected with anti-
nucleophosmin antibody. c U2OS cells expressing HA wild-type E2F7 (E2F7) or double DNA-binding mutant R185A/R334A. Nucleolin was detected
with anti-nucleolin antibody. d Diagram depicting a simpliﬁed model of UBF inﬂuence on Pol I activity resulting in increased pre-rRNA gene
expression leading to enhanced protein synthesis. Elevated levels of perinucleolar E2F7 results in E2F7 binding to the rRNA promoter resulting in
decreased pre-rRNA expression leading to decreased protein synthesis
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Actin forward: ATCGTGCGTGACATTAAGGAGAAG
reverse: CTGGAAGCAGCCGTGGCCGTCTCTTG.
E2F1 forward: AGGGCTCGATCCCGCTCCG reverse:
TAAAGCCAATAGGAACCGCCG Cdc6 forward: GGC
CTCACAGCGACTCTAAGA reverse: CTCGGACT
CACCACAAGC.
Reverse transcription qPCR
RNA was isolated using ReliaPrep kit (Promega)
according to the manufacturer’s instructions before
cDNA synthesis using random hexamers. qPCR was
performed using SYBR Green and quantiﬁed using the
2−ΔΔCT method. Pre-rRNA signals were normalised to
GAPDH. Primers targeting the pre-rRNA were set A:
forward: GAACGGTGGTGTGTCGTT reverse: GCGTC
TCGTCTCGTCTCACT. Set B: forward: GCCTTCTC
TAGCGATCTGAGAG reverse: CCATAACGGAGGCA
GAGACA.
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